Publication | Closed Access
Rituximab (anti-CD20) Adjunctive Therapy for Opsoclonus-Myoclonus Syndrome
134
Citations
40
References
2006
Year
Rituximab seems efficacious and safe as adjunctive therapy for OMS. Selective targeting of CSF B lymphocytes represents a novel and valuable paradigm shift in the therapy for centrally mediated paraneoplastic disorders.
| Year | Citations | |
|---|---|---|
Page 1
Page 1